Lupin Ltd

Stage 4 · Declining · week 3

As of 9 Oct 2026, Lupin is in Stage 4 — declining, a downtrend, in week 3 (since 23 Sep 2026). It closed at ₹1,957, 22.2% below its 52-week high and below its 200-day average, which is falling. In Health Care, 44.6% of stocks are in Stage 2.

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. More about the company

₹1,956.5
+1.01% today
₹89,469 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is LUPIN early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-22.2%
₹1,905.6 lo₹2,514.8 hi
22.2% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 3
1w13w26w
Week 3 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-13.2%
200 DMA: ₹2,254.5 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.40x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -2.8% vs MA50 -6.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-7.0%
3M
-21.6%
6M
-14.7%
YTD
-7.4%
1Y
-1.3%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
Sector has 74 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 49w
S2 19w
S4 14w
S2 28w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 49w → S3 3w → S2 19w → S3 7w → S2 7w → S3 4w → S4 7w → S1 4w → S4 14w → S1 9w → S2 28w → S3 4w → S2 8w → S3 3w → S4 2w current
Total tracked: 168 weeks across 15 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-07-06
4 appearances in last 60 days. First seen: 2024-07-09.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S4
Wk 3 · Vol 0.40x
2026-10-08S4
Wk 3 · Vol 0.68x
2026-10-07S4
Wk 2 · Vol 0.87x
2026-10-06S4
Wk 2 · Vol 1.19x
2026-10-05S4
Wk 2 · Vol 0.63x
2026-10-01S4
Wk 2 · Vol 0.91x
2026-09-30S4
Wk 2 · Vol 1.20x
2026-09-29S4
Wk 1 · Vol 1.05x
2026-09-28S4
Wk 1 · Vol 0.59x
2026-09-25S4
Wk 1 · Vol 0.48x
2026-09-24S4
Wk 1 · Vol 0.59x
2026-09-23S43→4
Wk 1 · Vol 0.71x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹2,166.1
200 DMA
₹2,254.5
52W High
₹2,514.8
52W Low
₹1,905.6
5D Low
₹1,936.9
Resistance levels (recent highs)
20d High
₹2,135
60d High
₹2,514.8
120d High
₹2,514.8
250d High
₹2,514.8
Next resistance
+9.1%
to 20d High
Ask the Market AI about LUPINAsk →
P/E (TTM)
19.5
Forward 22.4
Earnings Growth (YoY)
+89.0%
Revenue +31.9%
ROE
+26.9%
Profit margin +19.1%
Dividend Yield
0.53%
P/B 4.6
About this companyHealth Care· Pharmaceuticals

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women's health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.